本頁面由Tiger Trade Technology Pte. Ltd.提供服務

諾瓦瓦克斯醫藥

8.64
-0.0500-0.58%
盤後8.57-0.0696-0.81%19:59 EDT
成交量:200.60萬
成交額:1,726.82萬
市值:14.04億
市盈率:3.35
高:8.80
開:8.78
低:8.46
收:8.69
52周最高:11.97
52周最低:5.80
股本:1.62億
流通股本:1.37億
量比:0.68
換手率:1.47%
股息:- -
股息率:- -
每股收益(TTM):2.58
每股收益(LYR):2.58
淨資產收益率:-898.20%
總資產收益率:25.72%
市淨率:-10.99
市盈率(LYR):3.35

資料載入中...

2024/11/12

重要事件披露

Form 8-K - Current report
2024/11/05

重要事件披露

Form 8-K - Current report
2024/10/16

重要事件披露

Form 8-K - Current report
2024/10/03

重要事件披露

Form 8-K - Current report
2024/09/18

關聯方擬減持公告

Form 144 | NOVAVAX高管Filip Dubovsky擬減持7335股,總價約95331美元
2024/08/09

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/08

重要事件披露

Form 8-K - Current report
2024/08/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/20

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/06/18

關聯方擬減持公告

Form144|諾瓦瓦克斯公司董事James F.Young擬減持15000股,總價約20.57萬美元
2024/06/17

關聯方擬減持公告

Form144|諾瓦瓦克斯高管Filip Dubovsky擬減持13904股,總價約20萬美元
2024/06/14

重要事件披露

Form 8-K - Current report
2024/06/06

重要事件披露

Form 8-K - Current report
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/05/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/05/13

重要事件披露

Form 8-K - Current report
2024/05/10

重要事件披露

Form 8-K - Current report
2024/05/10

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/07

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]